Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.44 |
| ▸ | ASPH | Q12797 | 1/20 | 0.44 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | THRB | P10828 | 3/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30222084 | 0.91 | KEAP1 (0.50) | KEAP1KDM4EASPHKDM8NFE2L2 | |
| SCHEMBL604580 | 0.91 | KEAP1 (0.50) | KEAP1KDM4EASPHKDM8NFE2L2 | |
| SCHEMBL24338031 | 0.88 | KEAP1 (0.52) | KEAP1KDM4EASPHKDM8NFE2L2 | |
| Ammonia Solution, Strong SCHEMBL15377820 | 0.86 | KEAP1 (0.50) | KEAP1KDM4EASPHKDM8NFE2L2 | |
| SCHEMBL1713733 | 0.85 | KDM4E (0.54) | KEAP1KDM4EASPHKDM8NFE2L2 | |
| SCHEMBL222733 | 0.84 | KEAP1 (0.57) | KEAP1KDM4EASPHKDM8NFE2L2 | |
| SCHEMBL7056404 | 0.83 | ALDH1A1 (0.48) | KEAP1KDM4ENFE2L2KMT2AGFER | |
| SCHEMBL13575479 | 0.82 | DGAT1 (0.48) | KEAP1KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL19131130 | 0.81 | GABRP (0.47) | KEAP1KDM4ENFE2L2KMT2AGFER | |
| SCHEMBL17049160 | 0.81 | KDM4E (0.46) | KEAP1KDM4EASPHKDM8NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023215559-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ARIA PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215559-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ARIA PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| EP-3412660-B9 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | EA PHARMA CO LTD (JP) | 2021-04-14 | — | — | EP | disclosed |
| EP-3412660-B1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | EA PHARMA CO LTD (JP) | 2020-11-18 | — | — | EP | disclosed |
| EP-3064491-B1 | SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF | EA PHARMA CO LTD (JP) | 2020-01-08 | — | — | EP | disclosed |
| EP-3064491-B1 | SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF | EA PHARMA CO LTD (JP) | 2020-01-08 | — | — | EP | disclosed |
| US-10183932-B2 | Substituted oxopyridine derivatives and use thereof cardiovascular disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-01-22 | — | — | US | disclosed |
| EP-3412660-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | EA Pharma Co., Ltd. (JP) | 2018-12-12 | — | — | EP | disclosed |
| CN-108699008-A | Sulfamide derivative and pharmaceutical composition containing it | EA制药株式会社 | 2018-10-23 | — | — | CN | disclosed |
| CN-108164513-A | Substituted oxo pyridine derivative and its purposes in terms of cardiovascular disorder is treated | 拜耳制药股份公司 | 2018-06-15 | — | — | CN | disclosed |
| CN-101511836-A | Fused pyrimido compounds | ASTRAZENECA AB (SE) | 2009-08-19 | — | — | CN | disclosed |
| EP-2046793-A2 | FUSED PYRIMIDO COMPOUNDS | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| WO-2009024550-A1 | N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | N.V. ORGANON (NL) | 2009-02-26 | — | — | WO | disclosed |
| EP-2007773-A1 | THIAZOLYL DIHYDRO-INDAZOLES | Boehringer Ingelheim International GmbH (DE) | 2008-12-31 | — | — | EP | disclosed |
| WO-2008040951-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008003958-A2 | FUSED PYRIMIDO COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
| US-20070270401-A1 | Thiazolyl-Dihydro-Indazole | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-22 | — | — | US | disclosed |
| WO-2007113245-A1 | THIAZOLYL DIHYDRO-INDAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | WO | disclosed |
| US-4727080-A | BACTERICIDES, FUNGICIDES | PROVESAN S.A. (CH) | 1988-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270401-A1 | Thiazolyl-Dihydro-Indazole | MKI67, INSR, CCNT1 | KEAP1 491/4885KDM4E 3502/4885ASPH 3789/4885 |
| US-10183932-B2 | Substituted oxopyridine derivatives and use thereof cardiovascular disorders | OGFOD1, VASP, PNPO | KEAP1 1590/4885KDM4E 1342/4885ASPH 2224/4885 |
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | KEAP1 611/4885KDM4E 3977/4885ASPH 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.